JPRN-jRCT2080222427未知1 期
A Phase I study of ONO-7268MX2 in patients with hepatocellular carcinoma
ONO PHARMACEUTICAL CO.,LTD.0 个研究点目标入组 12 人开始时间: 2014年3月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients who have the history of histologically, cytologically or clinically confirmed hepatocellular carcinoma
- •2. Advanced hepatocellular carcinoma patients with no standard or adequate therapeutic options
- •3. Life expectancy of at least 3 months
排除标准
- •1. Patients with severe complication
- •2. Patients with multiple primary cancers
研究者
相似试验
未知
1 期
Phase I study of ONO-7268MX1Hepatocellular carcinomaJPRN-jRCT2080221888ONO PHARMACEUTICAL CO.,LTD.18
未知
1 期
Phase 1 study of ONO-7056Solid tumorJPRN-jRCT2080221709ONO PHARMACEUTICAL CO.,LTD.36
未知
2 期
ONO-2745 Phase II StudyPatients undergoing a surgery under general anesthesia requiring opiate analgesticsJPRN-jRCT2080221456ONO PHARMACEUTICAL CO.,LTD.90
招募中
1 期
Phase I study of RO7187797 in patients with Multiple myeloma.Multiple myelomaJPRN-jRCT2061220045anki Toshihiro6
进行中（未招募）
不适用
A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer. - NDTreatment of patients with metastatic hormone refractory prostate cancer.MedDRA version: 9.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2006-006136-21-ITERVIANO MEDICAL SCIENCES118